Cumberland Pharmaceuticals (CPIX) Rating Lowered to Hold at Zacks Investment Research
According to Zacks, “Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company’s lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients. “
Separately, TheStreet raised shares of Cumberland Pharmaceuticals from a d+ rating to a c- rating in a research report on Wednesday, April 10th.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.22. The firm had revenue of $11.90 million for the quarter, compared to analysts’ expectations of $10.70 million. Cumberland Pharmaceuticals had a negative net margin of 10.57% and a positive return on equity of 2.54%. As a group, equities research analysts anticipate that Cumberland Pharmaceuticals will post -0.22 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its position in shares of Cumberland Pharmaceuticals by 2.5% during the first quarter. Renaissance Technologies LLC now owns 390,777 shares of the specialty pharmaceutical company’s stock worth $2,270,000 after purchasing an additional 9,403 shares in the last quarter. BlueCrest Capital Management Ltd acquired a new position in shares of Cumberland Pharmaceuticals during the first quarter worth $63,000. Finally, Stonepine Capital Management LLC lifted its position in shares of Cumberland Pharmaceuticals by 7.8% during the fourth quarter. Stonepine Capital Management LLC now owns 1,313,429 shares of the specialty pharmaceutical company’s stock worth $7,920,000 after purchasing an additional 95,028 shares in the last quarter. 31.35% of the stock is currently owned by institutional investors and hedge funds.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Featured Article: FAANG Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.